The head of JFDA emphasizes advanced drug regulatory standards and compliance with WHO standards

(MENAFN – Jordan Times) AMMAN – Jordanian Food and Drug Administration (JFDA) Director General Nizar Mheidat stressed on Sunday that the administration continues to work towards achieving an advanced level of drug regulation and final approval of the drug as an internationally recognized regulatory body.

Mheidat added that the procedures are being carried out as part of the strengthening of regulatory systems (RSS) of the World Health Organization (WHO) and the accreditation of national regulatory authorities, Jordanian news agency Petra reported.

During the follow-up visit of the WHO expert mission to the programme, in the presence of the WHO representative in Jordan, Jamila Raiby Mheidat, stressed the importance of the visit for monitoring progress in implementing the recommendations based on the organisation’s previous visits.

The Director General added that these activities are in line with the institution’s strategy to apply the highest international standards in ensuring the quality, safety and effectiveness of medicines, as well as its commitment to supporting the pharmaceutical industry and increasing its competitiveness in line with the results of the Economic Modernisation Vision study.

Mheidat also praised JFDA’s continued efforts to develop and implement WHO recommendations, working together to improve the overall performance of the system, which will positively reflect the regulatory and supervisory role of the administration.

During the visit, JFDA Deputy Director General for Administration Maha Jaghbir was briefed on the country’s drug system and the progress made since October 2022 in terms of regulatory and supervisory functions carried out by the administration.

Jaghbir noted that these functions are critical to determining the maturity level of a regulatory body and include drug registration and approval processes, side effect monitoring, regulatory inspections, laboratory analysis and clinical trials, as well as the latest developments and updates related to these areas.

MENAFN30062024000028011005ID1108391511